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Abstract
Background: Hepatitis A virus (HAV), the causative agent of acute hepatitis in humans, is an
atypical Picornaviridae that grows poorly in cell culture. HAV titrations are laborious and time-
consuming because the virus in general does not cause cytopathic effect and is detected by
immunochemical or molecular probes. Simple HAV titration assays could be developed using
currently available viral construct containing selectable markers.
Results: We developed an antibiotic resistance titration assay (ARTA) based on the infection of
human hepatoma cells with a wild type HAV construct containing a blasticidin (Bsd) resistance gene.
Human hepatoma cells infected with the HAV-Bsd construct survived selection with 2 μg/ml of
blasticidin whereas uninfected cells died within a few days. At 8 days postinfection, the color of the
pH indicator phenol red in cell culture media correlated with the presence of HAV-Bsd-infected
blasticidin-resistant cells: an orange-to-yellow color indicated the presence of growing cells
whereas a pink-to-purple color indicated that the cells were dead. HAV-Bsd titers were
determined by an endpoint dilution assay based on the color of the cell culture medium scoring
orange-to-yellow wells as positive and pink-to-purple wells as negative for HAV. As a proof-of-
concept, we used the ARTA to evaluate the HAV neutralization potency of two commercially
available human immune globulin (IG) preparations and a WHO International Standard for anti-
HAV. The three IG preparations contained comparable levels of anti-HAV antibodies that
neutralized approximately 1.5 log of HAV-Bsd. Similar neutralization results were obtained in the
absence of blasticidin by an endpoint dilution ELISA at 2 weeks postinfection.
Conclusion: The ARTA is a simple and rapid method to determine HAV titers without using
HAV-specific probes. We determined the HAV neutralization potency of human IG preparations
in 8 days by ARTA compared to the 14 days required by the endpoint dilution ELISA. The ARTA
reduced the labour, time, and cost of HAV titrations making it suitable for high throughput
screening of sera and antivirals, determination of anti-HAV antibodies in human immune globulin
preparations, and research applications that involve the routine evaluation of HAV titers.
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Background
Hepatitis A Virus (HAV), a Picornaviridae that causes
acute hepatitis in humans, is a significant public health
problem in developing nations with approximately 1.4
million new infections per year [1]. The virus is mainly
transmitted via the fecal-oral route, either from person to
person or by ingestion of contaminated food and water.
Community wide outbreaks can result from the consump-
tion of oysters and mussels harvested from contaminated
waters, fresh produce from contaminated water-irrigated
fields, and food prepared by infected handlers [2-4]. For
example, a recent HAV outbreak originated from contam-
inated green onions resulted in over 600 infection cases
and 3 deaths [5]. Hepatitis A is an age-dependent disease,
and children 6 year old and younger in general develop a
subclinical form of the disease. Older children and adults
develop a more severe form of hepatitis A, which in some
rare instances can result in fulminant hepatitis. In devel-
oping countries, water- and food-borne HAV infections
are common during childhood, which induces life-long
immunity.
The overall incidence of HAV has decreased in recent years
in the United States and Europe [6,7] but the proportion
of travel-related cases has increased in the United States.
HAV vaccination and immune globulin (IG) are recom-
mended for international travellers who plan to visit
countries that are considered intermediate to high
endemic zones for HAV infection [7,8]. IG is recom-
mended in addition to vaccination for elderly persons
who are immunocompromised, have chronic liver dis-
ease, or have chronic medical conditions and are travel-
ling to endemic zones. HAV vaccine does not prevent
infection if administered three or more weeks post virus
infection, but protection is conferred by administration of
IG two weeks after exposure to the virus [9,10]. It has
recently been shown that both HAV vaccine and IG are
similarly effective for post-exposure prophylaxis within 2
weeks of the exposure to HAV [11]. IG preparations are
derived from pools of plasma from human donors. Anti-
HAV antibody levels vary among different lots of IG prep-
arations [12]. HAV vaccinated donors tend to have 10–50
fold lower anti-HAV titers than donors who were naturally
infected with HAV [13].
HAV grows poorly in cell culture and in general does not
induce cytopathic effect (CPE). Cytopathic strains of HAV
have been isolated but CPE takes a long time to develop,
the plaques are difficult to visualize, and CPE is depend-
ent on the multiplicity of infection [14,15]. Modified HAV
plaque assays that detect HAV antigen in fixed cells have
been developed but are time-consuming and laborious
[15-17]. ELISA-based endpoint dilution assays to titrate
HAV are simple to perform but require 2 weeks of incuba-
tion to detect antigen at the higher dilutions [18-23]. We
reported previously that the insertion of a blasticidin
resistance (Bsd) gene into the genome of wild type (wt)
HAV allowed the selection of a cell line with enhanced
susceptibility to wt HAV infection [24]. In the present
study, we used the HAV-Bsd construct to develop a rapid
and simple titration assay based on the selection of blasti-
cidin-resistant cells, and used this assay to evaluate the
HAV neutralization potency of commercially available
human IG preparations.
Results
Titration of HAV by the antibiotic resistance titration 
assay (ARTA)
To develop a simple and rapid titration method, we used
a wild type HAV construct containing a Bsd resistance
gene inserted into the 2A-2B junction [24]. In addition to
this selectable marker, this HAV-Bsd construct contained
an Ala-to-Val substitution at amino acid 216 of the 2B
protein (Figure 1) that enhanced its growth in cell culture
but did not attenuate the virus [25]. HAV-Bsd grew effi-
ciently in Huh7-A-I cells, a clone of human hepatoma
Huh7 cells that supports the stable growth of wt HAV
[24]. Huh7-A-I cells infected with HAV-Bsd were resistant
to a low concentration of blasticidin (2 mg/ml) that killed
uninfected cells. Since the HAV-Bsd-infected Huh7-A-I
cells, but not the uninfected cells, continued to metabo-
lize and acidify the cell culture media in the presence of
blasticidin, the color of the pH indicator in the cell culture
media could be used as a surrogate marker for the pres-
ence of HAV-Bsd-infected cells. In an endpoint dilution
assay using multiwell plates, the color of the cell culture
media could be used to identify HAV-Bsd positive and
negative wells without further processing of the plates. To
test our hypothesis, HAV-Bsd was titrated on 96-well
plates containing Huh7-A-I cells, and incubated at 35°C
for 8 days in the presence of 2 μg/ml blasticidin (Figure 2).
Examination of the 96-well plates under the microscope
showed that the orange-and-yellow wells contained
healthy cells whereas the pink and purple wells contained
rounded and detached dead cells (data not shown). This
direct correlation between the color of the cell culture
media and the presence or absence of live HAV-Bsd
infected cells was used to calculate viral titers using the
Reed and Muench method [26] and the ID50 computer
program.
Evaluation of total anti-HAV antibodies in human IG 
preparations
To determine whether the ARTA could be used to evaluate
the HAV neutralization potency of human IG prepara-
tions, we first analyzed the levels of anti-HAV antibodies
present in two commercially available human IG prepara-
tions from different manufacturers (Lab 1 and Lab 2). The
1st WHO International Standard for Hepatitis A Immu-
noglobulin (reconstituted as 100 IU/ml) was used as aVirology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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positive control IG preparation, and an anti-HAV anti-
body-negative human plasma donation containing ~1%
IgG was used as a negative control. All the IG preparation
stocks contained approximately 16% IgG solutions. Pres-
ence of anti-HAV antibodies in ten-fold dilutions of the IG
preparations was evaluated using the HAVAB EIA kit (Fig-
ure 3), a competitive assay with a cutoff value under
which samples are considered positive for anti-HAV anti-
bodies. All dilutions of the Lab 1, Lab 2, and the WHO
Standard IG preparations reacted similarly in the HAVAB
EIA test indicating that these IG preparations contained
comparable levels of anti-HAV antibodies. The absorb-
ance values of all the dilutions of the negative control
plasma were above the cutoff indicating the absence of
anti-HAV antibodies.
Evaluation of anti-HAV neutralizing antibodies in the 
human IG preparations by ARTA
The HAV neutralization potency of the IG preparations
was evaluated using the ARTA (Figure 4). To do so, neu-
tralization reactions containing 1% of human IG prepara-
tions and 105 TCID50 of HAV-Bsd in 0.3 ml of complete
cell culture media were incubated overnight at 4°C fol-
lowed by 1 h incubation at 37°C. Four-fold dilutions of
the neutralization reactions were titrated on 96-well plates
containing Huh7-A-I cell monolayers. After 4 h adsorp-
tion at 35°C, cells were washed 3 times, and 0.2 ml of
complete cell culture medium containing 2 μg/ml blasti-
cidin was added per well. Plates were placed in a 35°C
CO2 incubator for 8 days. The number of HAV-Bsd posi-
tive and negative wells was determined by visual examina-
tion of the orange-to-yellow and pink-to-purple wells,
respectively (Panel A). Viral titers (Panel B) were calcu-
lated using the Reed and Muench method. The Lab 1, Lab
2, and WHO standard IG preparations neutralized
approximately 1.5 log of HAV-Bsd. Treatment with the
negative control plasma had no effect on the HAV-Bsd
titer.
Comparison of the ARTA and ELISA methods to evaluate 
anti-HAV neutralizing antibodies levels in IG preparations
In a parallel experiment, the same neutralization reactions
used in the ARTA were titrated on 96-well plates contain-
ing Huh7-A-I cells. After viral absorption and washing,
complete cell culture medium without blasticidin was
added to the wells, and the plates were placed in a 35°C
CO2 incubator for 14 days. Cells were fixed with 10%
methanol and stained with an anti-HAV neutralizing
monoclonal antibody and HRP-labelled goat anti-mouse
secondary antibody. A TMB substrate was added to the
wells, color development was stopped by acidification,
and the plates were scanned in an ELISA plate reader.
Wells that developed at least two times the absorbance of
the uninfected control wells were considered positive for
HAV-Bsd. Viral titers were calculated by the Reed and
Muench method (Figure 5). The HAV-Bsd titers obtained
by ARTA and ELISA were similar indicating that these
titration systems are equivalent.
Discussion
The ARTA method to titrate HAV is based on the antibiotic
resistance of HAV-infected cells conferred by the blastici-
din deaminase gene inserted into the virus genome. In the
presence of blasticidin, HAV-Bsd-infected cells continue
Schematic representation of the genome of the HAV-Bsd Figure 1
Schematic representation of the genome of the HAV-Bsd. The infectious cDNA of wild type HM-175 strain of HAV 
(wt HAV) containing a A216V amino acid substitution in the 2B protein was used as the background to construct HAV-Bsd. 
The blasticidin resistance (Bsd) gene coding for the blasticidin deaminase was inserted into the 2A-2B junction of the infectious 
cDNA of HAV [24]. The Bsd gene was flanked by three G residues (gray box) and an HAV protease 3Cpro cleavage sites 
(dashed box) at each end. The three G residues form a hinge that facilitates the processing of the adjacent 3Cpro cleavage site 
and the release the blasticidin deaminase from the HAV polyprotein.Virology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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HAV titration by ARTA Figure 2
HAV titration by ARTA. (A) Huh7-A-I cells in 96-well plates were infected with ten-fold serial dilutions of HAV-Bsd and 
selected with 2 μg/ml blasticidin. Four wells were infected with each virus dilution. Plates were incubated for 8 days at 35°C 
and analyzed by the naked eye and under the microscope. A color photograph of the plate was taken a few minutes after 
removing the plate from the CO2 incubator. The color of the cell culture medium of all wells at dilution -2 to -4 and a single 
well at dilution -5 was orange-to-yellow, and these wells contained live cells as confirmed by microscope examination (not 
shown). The cell culture media color of three wells at dilution -5 and all the wells at dilutions -6 to -8 was pink to purple, and 
these wells contained dead cells as assessed under the microscope. The yellow and orange wells were considered positive for 
HAV-Bsd. (B) Four control wells containing Huh7-A-I cells were mock-infected and treated with 2 μg/ml blasticidin (+) or cell 
culture medium (-). The cells treated with blasticidin died and the cell culture media color turned pink-to-purple. The cells that 
did not receive the antibiotic were healthy and the color of the cell culture media was orange-to-yellow.Virology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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to metabolize and acidify the cell culture medium
whereas uninfected cells die and the cell culture media
turns pink to purple. At 8 days postinfection, there is a
100% correlation between the presence of surviving cells
in the wells and the color of the cell culture medium,
which obviates the use techniques of immunochemistry
or molecular biology to detect the presence of the virus in
the wells. Indeed, the HAV-Bsd titers determined by ARTA
at 8 days post-infection and by ELISA at 2 weeks postinfec-
tion were almost identical (compare Figures 4 and 5) indi-
cating that the ARTA and ELISA methods are equivalent.
Since the Huh7-A-I cells are highly sensitive to low con-
centrations of blasticidin, the viral titers can also be deter-
mined at 5 days postinfection before the change in the
color of the cell culture media becomes apparent by exam-
ination of the plates under the microscope (data not
shown).
HAV is commonly titrated in monkey kidney or human
fibroblast cell lines using attenuated strains of HAV that
are highly adapted to grow in these cell cultures and con-
tain a significant number of adapting mutations. For the
ARTA, we selected a wild type based HAV vector and the
human liver-derived Huh7-A-I cells to mimic as much as
possible the HAV infection conditions found in vivo.
Therefore, the ARTA described in this work is a better sys-
tem to evaluate anti-HAV antibodies and screen for antivi-
rals than other assays based on attenuated strains and
non-hepatic cell substrates.
Human IG preparations are recommended for HAV pre-
and post-exposure prophylaxis [11,12]. Although anti-
HAV specific antibodies in the IG preparations for human
use are evaluated by immunochemistry, an HAV neutrali-
zation test can provide a more direct evaluation of the
potency of the IG preparations. We used the ARTA to eval-
uate the HAV neutralization potency of two commercially
available IG preparations and a WHO anti-HAV standard.
These three IG preparations contained similar levels of
anti-HAV antibodies and had comparable neutralization
potencies. Our data showed that the ARTA is a simple,
rapid, and robust method to assess the HAV neutraliza-
tion potency of human IG preparations. The ARTA
described in this work reduces significantly the time,
effort, and cost of HAV titrations and could be exploited
for high throughput applications such as HAV epidemio-
logical studies, screening of antivirals, and the routine
assessment of the HAV neutralization potency of IG prep-
arations for human use.
Conclusion
The ARTA is a rapid and simple method to determine HAV
titers by examining the color of the cell culture medium.
HAV titers obtained by the ARTA and ELISA endpoint
Analysis of anti-HAV antibodies in IG preprations Figure 3
Analysis of anti-HAV antibodies in IG preprations. Semi-quantitative analysis of anti-HAV antibodies in the immune 
globulin preparations was performed with the HAVAB EIA kit. Ten-fold serial dilutions of the Lab 1, Lab 2, and WHO standard 
IG preparations in complete medium were tested in duplicates for the presence of anti-HAV antibodies. The negative control 
plasma control was also tested. The cutoff value was obtained from control reagents included with the HAVAB EIA kit. In this 
competitive assay, values above and below the cutoff were considered negative and positive, respectively. The means of dupli-
cate determinations are plotted and the standard deviations are shown as bars.Virology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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Determination of the HAV neutralization potency of human IG preparations by ARTA Figure 4
Determination of the HAV neutralization potency of human IG preparations by ARTA. HAV-Bsd was treated 
with 1% of Lab 1, Lab 2, WHO standard IG preparations, or negative plasma control, or mock-treated and titrated on 96-well 
plates containing Huh7-A-I cells. Four-fold serial dilutions of the neutralization reactions were inoculated in 6 wells per dilu-
tion. Complete medium with 2 μg/mL blasticidin was added to the wells, and the plates were incubated at 35°C for 8 days. (A) 
Color photograph of the 96-well plates obtained few minutes after taking the plates form the CO2 incubator. The mock-
treated control plate is not shown, and one well of the WHO Standard is shown empty due to microbial contamination. (B) 
HAV-Bsd titers were determined by the Reed and Muench method counting positive (yellow and orange) and negative (pink 
and purple) wells. The ID50 program was used to calculate the viral titers as the log10 of tissue culture infectious dose 50% 
(TCID50) and standard deviations, which are shown as bars.Virology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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dilution assays are comparable. However, the ARTA
requires shorter incubation times and no additional stain-
ing for viral antigens. We have successfully used the ARTA
to evaluate the HAV neutralization potency of human IG
preparations. The ARTA is an ideal assay to determine
HAV titers for research purposes, and could also be used
for large scale epidemiological studies, high throughput
screening of antivirals, and the evaluation of anti-HAV
antibodies in IG preparations for human use.
Methods
Cells and viruses
Huh7-A-I cells, a clone of human hepatoma Huh7 cells
that support the stable growth of wt HAV in cell culture
[24], were grown in Dulbeco's modified Eagle's medium
supplemented with 10% fetal bovine serum (complete
medium) at 37°C in a 5% CO2 incubator. The HAV-Bsd
construct was derived from pHAV8Y-Bsd, which codes for
the infectious cDNA of the wild type HM-175 strain of
human HAV containing a A216V substitution at amino
acid 216 of the 2B protein and a blasticidin resistance
gene at the 2A-2B junction [24]. HAV-Bsd was grown in
Huh7-A-I cells in the presence of 2 μg/ml blasticidin, and
viral stocks were prepared by washing infected cell cul-
tures and subjecting the cells to 3 freeze-and-thaw cycles.
IG preparations
Stocks of commercially available liquid IG preparations,
Immune Globulin (Human) and Immune Globulin Sub-
cutaneous (Human), from two different Manufactures
(Lab 1 and Lab 2) and the 1st WHO International Stand-
ard for Hepatitis A Immunoglobulin [27] containing 100
IU anti-HAV antibodies per ml were prepared as 16% IgG
solutions. A stock of an anti-HAV antibody-negative
Determination of the HAV neutralization potency of human IG preparations by ELISA Figure 5
Determination of the HAV neutralization potency of human IG preparations by ELISA. HAV-Bsd was treated 
with 1% IG preparations as indicated in Figure 4 and titrated in 96-well plates containing Huh7-A-I cells. Four-fold serial dilu-
tions of the neutralization reactions were inoculated in 8 wells per dilution and incubated in the absence of blasticidin for 2 
weeks at 35°C. Cells were fixed and stained with anti-HAV mAb K2-4F2 and peroxidase-labeled goat anti-mouse antibodies. 
TMB substrate was added and color development was stopped by acidification. Absorbance at 450 nm was measured in an 
ELISA plate reader. Wells that developed at least 2 times the absorbance of mock-infected controls were considered positive 
for HAV-Bsd. Viral titers were calculated as in Figure 4.Virology Journal 2008, 5:155 http://www.virologyj.com/content/5/1/155
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human plasma donation prepared as a 1% IgG solution
was used as negative control.
Determination of anti-HAV antibodies in immune globulin 
preparations
IG preparations were diluted in complete medium and
levels of anti-HAV antibodies were determined by the
HAVAB EIA test (Abbott Laboratories) according to the
manufacturer's instructions. Samples with OD values
above the cutoff value were considered nonreactive, while
those with OD values less than or equal to the cutoff value
were considered reactive for anti-HAV antibodies. Sam-
ples were analyzed in duplicates, and the means and
standard deviations of the OD from each dilution were
calculated and plotted.
Neutralization assay
Neutralization reactions in 0.3 ml of complete medium
containing 1% IG preparations and 105 TCID50 HAV-Bsd
were incubated rotating overnight at 4°C followed by 1 h
at 37°C. The neutralization reactions were diluted in com-
plete medium and titrated on 96-well plates containing
confluent monolayers of Huh7-A-I cells.
HAV titer determination by ARTA
Four- or ten-fold dilutions of the neutralization reaction
in complete medium were titrated on 96-well plates con-
taining confluent monolayers of Huh7-A-I cells. Four or
six replica wells were inoculated per dilution. Plates were
washed three times with serum free medium followed by
the addition of 0.2 ml complete medium containing 2 μg/
ml blasticidin per well. Plates were placed in a CO2 incu-
bator at 35°C. After 8 days, plates were observed under
the microscope, and wells containing cells were scored as
positive. Alternatively, the plates were examined by the
naked eye to determine the color of the cell culture media
in each well. Orange and yellow wells were considered
positive and pink and purple wells were considered nega-
tive. Viral titers were calculated using the Reed and
Muench method [26].
HAV titer determination by ELISA
The same neutralization reactions evaluated by ARTA
were titrated in parallel by an endpoint dilution ELISA in
96-well plates containing Huh7-A-I cells but in the
absence of blasticidin. Eight replica wells were inoculated
per dilution, and plates were placed in a CO2 incubator at
35°C. Two weeks post-infection, HAV-Bsd titers were
determined by ELISA [24]. Briefly, cells were fixed with
90% methanol, and stained with a 1:4,000 dilution of
anti-HAV monoclonal antibody K2-4F2 (Commonwealth
Labs), and a 1:5,000 dilution of peroxidase-labeled goat
anti-mouse secondary antibody. TMB one-component
peroxidase substrate (KPL Inc) was added to the wells, and
the colorimetric reaction was stopped with 1% H2SO4. An
increase in absorbance of at least two folds above the
uninfected negative control wells was considered positive.
Viral titers were determined by the method of Reed and
Muench [26].
Statistical analysis
Viral titers and standard deviations were calculated using
the ID50 program developed by John L. Spouge (National
Center for Biotechnology Information, NIH).
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